Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 5/20 | 0.38 |
| ▸ | CDK2 | P24941 | 5/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 12/20 | 0.35 |
| ▸ | DRD2 | P14416 | 9/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27326920 | 0.83 | NR4A2 (0.43) | — | |
| SCHEMBL10150924 | 0.83 | CCNE1 (0.41) | CCNE1CDK2GSK3BDRD3DRD2 | |
| SCHEMBL682873 | 0.79 | HSD17B10 (0.41) | CCNE1CDK2GSK3BFEN1PIK3CG | |
| SCHEMBL873455 | 0.79 | HSP90AB1 (0.38) | CCNE1CDK2GSK3BFEN1 | |
| SCHEMBL17916146 | 0.78 | CCNE2 (0.44) | CCNE1CDK2PIK3CG | |
| SCHEMBL22723931 | 0.78 | HTT (0.40) | CCNE1CDK2GSK3BFEN1PIK3CG | |
| SCHEMBL27368805 | 0.76 | NR4A2 (0.35) | CCNE1CDK2 | |
| SCHEMBL23331071 | 0.71 | CCNE1 (0.42) | CCNE1CDK2GSK3BDRD3DRD2 | |
| SCHEMBL21578172 | 0.71 | — | — | |
| SCHEMBL8532973 | 0.69 | ALDH1A1 (0.45) | DRD3DRD2FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564239-B9 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN INC (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| EP-3564239-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | Shenzhen Immunova Pharmaceutical Co., Ltd. (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-9695182-B2 | Chemical compounds (derivatives) and their application for the treatment of oncological diseases | LIMITED LIABILITY COMPANY “NATIONAL PHARMACEUTICAL TECHNOLOGIES” (RU) | 2017-07-04 | — | — | US | disclosed |
| US-20160200729-A1 | NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES | LIMITED LIABILITY COMPANY (RU) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200729-A1 | NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES | BRAF, CNKSR1, RAF1 | CCNE1 406/4885CDK2 33/4885GSK3B 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.